News & Updates
Filter by Specialty:
RELIEVE-AD: Atopic dermatitis patients see rapid, sustained improvements with dupilumab
The biologic dupilumab appears to be a hit with atopic dermatitis (AD) patients treated in the real-world setting, with patients experiencing prompt improvements in multiple aspects of disease control that persisted through 1 year, as shown in the results of the RELIEVE-AD* study.
RELIEVE-AD: Atopic dermatitis patients see rapid, sustained improvements with dupilumab
17 Jun 2022
Dostarlimab a miraculous cure for mismatch repair-deficient, locally advanced rectal cancer?
Use of dostarlimab, a single-agent programmed death 1 (PD-1) monoclonal antibody, appears to have successfully cured mismatch repair-deficient, locally advanced rectal cancer, reports a recent study.
Dostarlimab a miraculous cure for mismatch repair-deficient, locally advanced rectal cancer?
16 Jun 2022
Fixed-dose albuterol/budesonide an effective rescue med in moderate-to-severe asthma
A fixed-dose combination of albuterol and budesonide, delivered as needed, reduced the risk of severe exacerbations in patients with moderate-to-severe asthma inadequately controlled with corticosteroid maintenance therapy, according to results of the phase III MANDALA trial presented at ATS 2022.
Fixed-dose albuterol/budesonide an effective rescue med in moderate-to-severe asthma
15 Jun 2022
Is SGLT-2 inhibitor better than metformin as first-line T2D treatment?
Use of sodium–glucose cotransporter-2 inhibitors (SGLT-2i) as first-line treatment for type 2 diabetes (T2D) delivers a comparable risk for myocardial infarction (MI), stroke, and mortality; a lower risk for hospitalization for heart failure (HHF)/mortality and HHF; and a similar safety profile, except for a higher risk for genital infections, when compared to treatment with metformin, a study has found.
